Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs ProShares Ultra Gold ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while ProShares Ultra Gold ETF trades at $45.54 (market cap $730.54M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 10.3× ProShares Ultra Gold ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and ProShares Ultra Gold ETF for 25 Days on average.
| SYRE | UGL | |
|---|---|---|
Market Cap | $7.52B | $730.54M |
Volume | 1,441,031 | 1,700,224 |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.92 | $85.62 |
52-Week Low | $22.18 | $42.79 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
UGL is trading at $45.70, down 0.39% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX. Financial ratios are unavailable, limiting fundamental assessment. Recent news highlights gold price volatility amid shifting Fed rate expectations and Treasury yield pressures, influencing sentiment.
The outlook remains cautious due to technical weakness and macroeconomic headwinds. Risks include persistent rate-hike uncertainty and gold market sensitivity. Investment potential hinges on future financial disclosures and gold price stabilization, but current data gaps and bearish signals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
